46 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
demonstrated significant progress in transforming the Company’s business model and product portfolio for long-term sustainable growth,” said Denny
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
4 Mar 24
Completion of Acquisition or Disposition of Assets
6:22am
, reduce interest costs, reduce headcount and overhead costs, thereby significantly advancing our efforts to become a sustainable and growing oncology
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
5 Feb 24
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
8:09am
. “This will allow us to move forward with a strengthened balance sheet, supporting sustainable revenue growth in our oncology business and better aligning with our
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
sustainable and growing oncology business.”
Coherus’ oncology assets include the UDENYCA® (pegfilgrastim-cbqv) franchise, with three FDA-approved